Impacting Human Health: Moderna’s 2021 ESG Report

Body

In its 2021 ESG Report, Moderna outlines its corporate responsibility strategy and defines five guiding focus areas for ongoing and future efforts:

  • Medicines for patients
  • Employees
  • Environment
  • Community
  • Governance and ethics

The report also includes updates to the progress Moderna has made to date:

  • 25% of total doses of its COVID-19 vaccine in 2021 were delivered to low- and middle-income countries.
  • 40% of Moderna’s U.S. workforce identifies as racially or ethnically diverse, up from 35% in 2020.
  • Moderna announced its Global Public Health Strategy to:
    • Advance vaccines targeting 15 pathogens identified as the biggest public health risks into clinical studies by 2025
    • Launch mRNA Access
    • Expand its COVID-19 patent pledge
    • Establish an mRNA Manufacturing Facility in Kenya, Africa
  • Moderna formed a new collaboration with the Institute for Life Changing Medicines to develop a new mRNA therapeutic (mRNA-3351) for Crigler-Najjar type 1 (CN-1), an ultra-rare disease. The goal of this partnership is to make an mRNA therapy for the treatment of CN-1 available at no cost to patients and their families.
  • Moderna affirmed its commitment to sustainability by pledging to achieve net-zero carbon emissions in by 2030. With its engineering and manufacturing teams, Moderna is designing the company roadmap to embed sustainability by design in its current facilities and future manufacturing sites.

To read more, please visit: https://www.modernatx.com/responsibility/our-commitment

Media Contact:
Katherine O’Malley
Executive Director, Communications

Homepage 1st Row Image
"Impacting Human Health 2021 ESG Report" with Moderna logo
Square
"Impacting Human Health 2021 ESG Report" with Moderna logo
Client
Homepage 2nd Row Image
"Impacting Human Health 2021 ESG Report" with Moderna logo
Report Image
"Impacting Human Health 2021 ESG Report" with Moderna logo
Intro

The past year was one of monumental impact and change for Moderna. In the fight against the pandemic, the Moderna team showed relentlessness under tight timelines and COVID-related challenges, while advancing its COVID-19 vaccine and broad pipeline of mRNA medicines, always with a deep sense of purpose and care for patients, employees, the environment, and the community. With the publication of its very first Environmental, Social and Governance Report, Moderna reflects on how the COVID-19 pandemic has exacerbated inequalities around the world, the urgent need to increase access to quality healthcare and medicines, to close the opportunity gap, particularly in underserved communities, and to save the planet from the devastating impacts of climate change.

ReportAlert Site
On
ReportAlert Email
On
CSRWire Site
On
EthicalPerformance Site
Off
3BL FMR
On
Email Approved
No
Email Sent
No
Choose Email Template
117873
Campaign ID
dc24f2355e
Client Logo - Override
Moderna Logo
Choose Audience Group
Report Alert
D7 ID
747396